Skip to main content

Table 3 Effect of A. hydaspica AHE fraction on hematological parameters

From: Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats

Treatment (mg/kg)

RBC (106/μl)

WBC (103/μl)

Hb (g/Dl)

PCV (%)

MCV (fL)

MCH (pg)

MCHC (g/dL)

Neutrophil (103/μl)

Lymphocytes (103/μl)

Platelets (103/mm3)

Control

8.01 ± 0.33

9.12 ± 0.51

13.13 ± 0.87

43.9 ± 1.22

73.11 ± 2.54

16.11 ± 1.11

29.57 ± 2.50

34.53 ± 2.71

22.11 ± 2.56

709 ± 3.22

DOX

4.61 ± 0.37a

5.11 ± 0.44a

10.08 ± 0.79a

22.65 ± 1.45a

59.98 ± 2.68a

10.20 ± 0.99a

19.89 ± 1.98a

21.10 ± 2.54a

47.81 ± 2.76a

386 ± 3.29a

AHE alone

8.10 ± 0.41b

9.19 ± 0.49b

13.23 ± 0.81b

45.11 ± 1.24b

74.01 ± 2.35b

16.55 ± 1.01b

29.9 ± 2.11b

35.11 ± 2.67b

21.21 ± 2.88b

714 ± 3.11b

DOX+ AHE (200)

6.01 ± 0.39a*,c**

6.67 ± 0.43a,b,c

11.01 ± 0.76a**,b,c

30.12 ± 1.56a,b,c

63.9 ± 2.60a,c*

12.87 ± 0.98a,b**,c*

22.34 ± 1.89a,c**

24.41 ± 2.71a,c**

39.65 ± 2.78a*,b,c**

498 ± 3.21a,b,c

DOX+ AHE (400)

7.95 ± 0.42b

8.98 ± 0.47b

12.80 ± 0.79b

39.50 ± 1.60b

68.99 ± 2.22b

14.98 ± 1.06b

27.65 ± 2.02b

30.22 ± 2.45b

27.32 ± 2.81a*,b

667 ± 3.78a,b

DOX+ Sily

7.96 ± 0.40b

8.97 ± 0.45b

12.88 ± 0.81b

39.23 ± 1.71b

68.56 ± 2.44b

15.08 ± 1.04b

27.9 ± 2.00b

31.01 ± 2.66b

27.50 ± 2.56a*,b

670 ± 3.66a,b

  1. Data expressed as mean ± SEM (n = 6)
  2. asignificant difference Vs. Control group at p < 0.0001
  3. bsignificant difference Vs. DOX-treated group at p < 0.0001
  4. csignificant difference of DOX + AHE (200 mg/kg) treated group Vs. DOX + AHE (400 mg/kg) treated group at p < 0.001
  5. *, **indicate significance at p < 0.05 and p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin